| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $525,663 | 1 | 25 |
Sells | $49,089 | 3 | 75 |
| Hawryluk P. Kent | President & CEO | 1 | $525,663 | 1 | $17,931 | $507,732 |
| Azoulay Salomon | Chief Medical Officer | 0 | $0 | 2 | $31,159 | $-31,159 |
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) …
Over the last 12 months, insiders at MBX Biosciences, Inc. Common Stock have bought $525,663 and sold $49,089 worth of MBX Biosciences, Inc. Common Stock stock.
On average, over the past 5 years, insiders at MBX Biosciences, Inc. Common Stock have bought $6.53M and sold $49,089 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hawryluk P. Kent (President & CEO) — $525,663.
The last purchase of 18,500 shares for transaction amount of $525,663 was made by Hawryluk P. Kent (President & CEO) on 2026‑03‑13.
| 2026-08-04 | Sale | Azoulay Salomon | Chief Medical Officer | 370 0.0007% | $65.77 | $24,335 | -14.87% | |
| 2026-05-06 | Sale | Hawryluk P. Kent | President & CEO | 607 0.0017% | $29.54 | $17,931 | +77.21% | |
| 2026-05-06 | Sale | Azoulay Salomon | Chief Medical Officer | 231 0.0006% | $29.54 | $6,824 | +77.21% | |
| 2026-03-13 | Hawryluk P. Kent | President & CEO | 18,500 0.0559% | $28.41 | $525,663 | +88.30% | ||
| 2025-10-20 | Hawryluk P. Kent | President & CEO | 20,000 0.0571% | $13.64 | $272,790 | +146.24% | ||
| 2025-10-17 | Hoerter Steven L. | director | 20,000 0.0597% | $13.25 | $264,984 | +163.99% | ||
| 2025-09-26 | Heron Patrick J | 666,666 2.0401% | $18.00 | $12M | +88.35% |
| Hawryluk P. Kent | President & CEO | 727667 1.5109% | $40.02M | 2 | 1 | +146.24% |
| Heron Patrick J | 5219440 10.8377% | $287.07M | 1 | 0 | +88.35% | |
| Hoerter Steven L. | director | 20000 0.0415% | $1.1M | 1 | 0 |
$52,263,649 | 70 | 1.18% | $2.49B | |
$586,486,795 | 47 | 4.28% | $2.38B | |
$154,047,855 | 36 | 79.21% | $2.21B | |
$28,907,358 | 35 | 41.41% | $2.28B | |
$1,275,975,557 | 32 | 19.44% | $3.54B |
| Increased Positions | 96 | +84.96% | 7M | +15.12% |
| Decreased Positions | 49 | -43.36% | 7M | -13.79% |
| New Positions | 44 | New | 4M | New |
| Sold Out Positions | 25 | Sold Out | 3M | Sold Out |
| Total Postitions | 160 | +41.59% | 48M | +1.33% |
| Frazier Life Sciences Management, L.P. | $203,219.00 | 14.78% | 6.65M | +666,666 | +11.14% | 2025-09-30 |
| Wellington Management Group Llp | $147,353.00 | 10.72% | 4.82M | +3M | +112.8% | 2025-09-30 |
| Orbimed Advisors Llc | $122,288.00 | 8.9% | 4M | 0 | 0% | 2025-09-30 |
| Nea Management Company, Llc | $110,423.00 | 8.03% | 3.61M | 0 | 0% | 2025-09-30 |
| Deep Track Capital, Lp | $96,233.00 | 7% | 3.15M | +961,408 | +43.93% | 2025-09-30 |
| Nvp Associates, Llc | $65,265.00 | 4.75% | 2.14M | 0 | 0% | 2025-09-30 |
| Ecor1 Capital, Llc | $64,876.00 | 4.72% | 2.12M | +973,810 | +84.69% | 2025-09-30 |
| Kynam Capital Management, Lp | $61,100.00 | 4.44% | 2M | +2M | New | 2025-09-30 |
| Blackrock, Inc. | $59,800.00 | 4.35% | 1.96M | +945,915 | +93.51% | 2025-09-30 |
| Vanguard Group Inc | $51,243.00 | 3.73% | 1.68M | +633,678 | +60.72% | 2025-09-30 |